<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MYALEPT- metreleptin injection, powder, lyophilized, for solution </strong><br>Amylin Pharmaceuticals, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use MYALEPT safely and effectively. See full prescribing information for MYALEPT.<br><br>MYALEPT™ (metreleptin) for injection for subcutaneous use <br>Initial U.S. Approval: 2014</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING:  RISK OF ANTI-METRELEPTIN ANTIBODIES WITH NEUTRALIZING ACTIVITY AND RISK OF <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">LYMPHOMA</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING:  RISK OF ANTI-METRELEPTIN ANTIBODIES WITH NEUTRALIZING ACTIVITY AND RISK OF <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">LYMPHOMA</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">MYALEPT is a leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>. (<a href="#S1">1</a>) </p>
<p class="Highlighta"><span class="Bold">Limitations of Use</span> </p>
<dl>
<dt>•</dt>
<dd>The safety and effectiveness of MYALEPT for the treatment of complications of partial <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> have not been established. (<a href="#S1">1</a>)</dd>
<dt>•</dt>
<dd>The safety and effectiveness of MYALEPT for the treatment of liver disease, including nonalcoholic steatohepatitis (NASH), have not been established. (<a href="#S1">1</a>)</dd>
<dt>•</dt>
<dd>MYALEPT is not indicated for use in patients with HIV-related <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>. (<a href="#S1">1</a>)</dd>
<dt>•</dt>
<dd>MYALEPT is not indicated for use in patients with metabolic disease, without concurrent evidence of generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>. (<a href="#S1">1</a>)</dd>
</dl>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Administer as a subcutaneous injection once daily after the lyophilized cake is reconstituted with Bacteriostatic Water for Injection (BWFI) or preservative-free sterile Water for Injection (WFI). (<a href="#S2.1">2.1</a>) </p>
<p class="Highlighta">The recommended daily dosages are:  </p>
<dl>
<dt>•</dt>
<dd>Body weight 40 kg or less: starting dose 0.06 mg/kg/day, increase or decrease by 0.02 mg/kg to a maximum daily dose of 0.13 mg/kg. (<a href="#S2.1">2.1</a>)</dd>
<dt>•</dt>
<dd>Males greater than 40 kg body weight: starting dose 2.5 mg/day, increase or decrease by 1.25 mg to 2.5 mg/day to a maximum dose of 10 mg/day. (<a href="#S2.1">2.1</a>)</dd>
<dt>•</dt>
<dd>Females greater than 40 kg body weight: starting dose 5 mg/day, increase or decrease by 1.25 mg to 2.5 mg/day to a maximum dose of 10 mg/day. (<a href="#S2.1">2.1</a>)</dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">MYALEPT is supplied as a sterile, white, solid, lyophilized cake of 11.3 mg metreleptin per vial to deliver 5 mg per mL when reconstituted in 2.2 mL of BWFI or WFI. (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>General <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> not associated with congenital leptin deficiency. (<a href="#S4.1">4.1</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to metreleptin. (<a href="#S4.2">4.2</a>)</dd>
</dl></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Anti-metreleptin antibodies with neutralizing activity: Could inhibit endogenous leptin action and/or result in loss of MYALEPT efficacy. Test for neutralizing antibodies in patients with severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or loss of efficacy during MYALEPT treatment. (<a href="#S5.1">5.1</a>)</dd>
<dt>•</dt>
<dd>T-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>: Carefully consider benefits and risks of treatment with MYALEPT in patients with significant hematologic abnormalities and/or acquired generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>.  (<a href="#S5.2">5.2</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>: A dose adjustment, including possible large reductions, of insulin or insulin secretagogue may be necessary. Closely monitor blood glucose in patients on concomitant insulin or insulin secretagogue therapy. (<a href="#S5.4">5.4</a>)</dd>
<dt>•</dt>
<dd>Autoimmunity: <span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune disorder</span> progression has been observed in patients treated with MYALEPT. Carefully consider benefits and risks of MYALEPT treatment in patients with autoimmune disease.  (<a href="#S5.5">5.5</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> (e.g., <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> or generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>) have been reported. Patient should promptly seek medical advice regarding suspected reactions. (<a href="#S5.6">5.6</a>)</dd>
<dt>•</dt>
<dd>Benzyl Alcohol Toxicity: Preservative-free sterile WFI recommended for neonates and infants. (<a href="#S5.7">5.7</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common in clinical trials (≥10%): <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, decreased weight, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. (<a href="#S5.4">5.4</a>,<a href="#S6.1"> 6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Pregnancy: MYALEPT should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. No adequate and well-controlled studies have been conducted with metreleptin in pregnant women. (<a href="#S8.1">8.1</a>)</dd>
<dt>•</dt>
<dd>Nursing Mothers:  Discontinue drug or nursing. (<a href="#S8.3">8.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div><div></div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 6/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: RISK OF ANTI-METRELEPTIN ANTIBODIES WITH NEUTRALIZING ACTIVITY AND RISK OF <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">LYMPHOMA</span></a></h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	Patients with Generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">Lipodystrophy</span></a></h2>
<h1><a href="#section-2" class="toc">2	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Recommended Dosing</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	 MYALEPT Preparation and Storage</a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Administration Instructions</a></h2>
<h2><a href="#section-2.4" class="toc">2.4	Dosage Adjustments of Medications Known to Cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></a></h2>
<h2><a href="#section-2.5" class="toc">2.5	Discontinuation in Patients at Risk for <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></a></h2>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4	CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1	General <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span></a></h2>
<h2><a href="#section-4.2" class="toc">4.2	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h1><a href="#section-5" class="toc">5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Risk for Development of Antibodies that Neutralize Endogenous Leptin and/or MYALEPT</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	<span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3	MYALEPT REMS Program</a></h2>
<h2><a href="#section-5.4" class="toc">5.4	<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> with Concomitant Use with Insulin and Insulin Secretagogues</a></h2>
<h2><a href="#section-5.5" class="toc">5.5	Autoimmunity</a></h2>
<h2><a href="#section-5.6" class="toc">5.6	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7	Benzyl Alcohol Toxicity</a></h2>
<h1><a href="#section-6" class="toc">6	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Immunogenicity</a></h2>
<h1><a href="#section-7" class="toc">7	DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8	USE IN SPECIFIC POPULATIONS  </a></h1>
<h2><a href="#section-8.1" class="toc">8.1	Pregnancy </a></h2>
<h2><a href="#section-8.2" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4	Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5	Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10	OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11	DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2	Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3	Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14	CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1	Open-Label, Single-Arm Study</a></h2>
<h1><a href="#section-14" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1	How Supplied</a></h2>
<h2><a href="#section-14.2" class="toc">16.2	Storage and Handling</a></h2>
<h1><a href="#section-15" class="toc">17	PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="ID_80279e9f-8089-4553-bf59-0ba65678e38f"></a><a name="section-1"></a><p></p>
<h1>WARNING: RISK OF ANTI-METRELEPTIN ANTIBODIES WITH NEUTRALIZING ACTIVITY AND RISK OF <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">LYMPHOMA</span></h1>
<p class="First"><span class="Bold">Anti-metreleptin antibodies with neutralizing activity have been identified in patients treated with MYALEPT. The consequences of these neutralizing antibodies are not well characterized but could include inhibition of endogenous leptin action and/or loss of MYALEPT efficacy. Severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and/or worsening metabolic control have been reported. Test for anti-metreleptin antibodies with neutralizing activity in patients who develop severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or show signs suspicious for loss of MYALEPT efficacy during treatment. Contact AstraZeneca at 1-866-216-1526 for neutralizing antibody testing of clinical samples [see <span class="Italics"><a href="#S4.1">Contraindications (4.1)</a></span> and <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</span></p>
<p><span class="Bold">T-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> has been reported in patients with acquired generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>, both treated and not treated with MYALEPT. Carefully consider the benefits and risks of treatment with MYALEPT in patients with significant hematologic abnormalities and/or acquired generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> [see <span class="Italics"><a href="#S5.2">Warnings and Precautions (5.2)</a></span>].</span></p>
<p><span class="Bold">Because of these risks associated with the development of anti-metreleptin antibodies that neutralize endogenous leptin and/or MYALEPT and the risk for <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, MYALEPT is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MYALEPT REMS PROGRAM [see <span class="Italics"><a href="#S5.3">Warnings and Precautions (5.3)</a></span>].</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1	Patients with Generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">Lipodystrophy</span></h2>
<p class="First">MYALEPT (metreleptin) for injection is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>.</p>
<p><span class="Bold">Limitations of Use</span></p>
<dl>
<dt>•</dt>
<dd>The safety and effectiveness of MYALEPT for the treatment of complications of partial <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> have not been established.</dd>
<dt>•</dt>
<dd>The safety and effectiveness of MYALEPT for the treatment of liver disease, including nonalcoholic steatohepatitis (NASH), have not been established.</dd>
<dt>•</dt>
<dd>MYALEPT is not indicated for use in patients with HIV-related <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>.</dd>
<dt>•</dt>
<dd>MYALEPT is not indicated for use in patients with metabolic disease, including <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus and <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, without concurrent evidence of congenital or acquired generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2	DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Recommended Dosing</h2>
<p class="First">See Table 1 for the recommended daily dose and maximum recommended daily dose in adults and pediatric patients.</p>
<p>Based on clinical response (e.g., inadequate metabolic control) or other considerations (e.g., tolerability issues, excessive <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> [especially in pediatric patients]), MYALEPT dosage may be decreased or increased to the maximum dosage listed in Table 1.</p>
<a name="_RefID0EHIAC"></a><table>
<caption><span>Table 1:  MYALEPT Recommended Dosage</span></caption>
<col width="27%">
<col width="21%">
<col width="22%">
<col width="24%">
<thead><tr class="First Last">
<th class="Botrule Rrule Toprule"><span class="Bold">Baseline Weight</span></th>
<th class="Botrule Rrule Toprule">
<span class="Bold">Starting Daily Dose </span><br><span class="Bold">(injection volume)</span>
</th>
<th class="Botrule Rrule Toprule">
<span class="Bold">Dose Adjustments</span><br><span class="Bold">(injection volume)</span>
</th>
<th class="Botrule Toprule">
<span class="Bold">Maximum Daily Dose</span><br><span class="Bold">(injection volume)</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Rrule Toprule" valign="top"><p class="First">Less than or equal to 40 kg<br>(males and females) </p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">0.06 mg/kg<br>(0.012 mL/kg)</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">0.02 mg/kg<br>(0.004 mL/kg)</p></td>
<td class="Botrule Toprule" align="center" valign="top"><p class="First">0.13 mg/kg<br>(0.026 mL/kg)</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First">Males greater than 40 kg</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2.5 mg<br>(0.5 mL)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.25 mg (0.25 mL) to<br>2.5 mg (0.5 mL)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">10 mg<br>(2 mL)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" valign="top"><p class="First">Females greater than 40 kg</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5 mg <br>(1 mL)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.25 mg (0.25 mL) to<br>2.5 mg (0.5 mL)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">10 mg<br>(2 mL)</p></td>
</tr>
</tbody>
</table>
<p>MYALEPT should be administered once daily at the same time every day. MYALEPT can be administered any time of day without regard to the timing of meals.</p>
<p>Instruct patients that if a dose is missed, administer the dose as soon as noticed, and resume the normal dosing schedule the next day. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	 MYALEPT Preparation and Storage</h2>
<p class="First">Healthcare practitioners should provide proper training to patients and caregivers regarding how to prepare and administer the correct dose of MYALEPT prior to self-use. The patients and caregivers should prepare and administer the first dose of MYALEPT under the supervision of a qualified healthcare professional.</p>
<p>Instruct patients to store the vials of lyophilized powder in their carton in the refrigerator as soon as received [see <span class="Italics"><a href="#S16.2">How Supplied/Storage and Handling (16.2)</a></span>].</p>
<p>MYALEPT can be reconstituted aseptically with 2.2 mL of sterile Bacteriostatic Water for Injection (BWFI), USP (0.9% benzyl alcohol), or with 2.2 mL of sterile Water for Injection (WFI).</p>
<p>When reconstituted in BWFI, MYALEPT solution can be used within 3 days when stored in the refrigerator between 36°F and 46°F (2°C and 8°C) and protected from light [see <span class="Italics"><a href="#S16.2">How Supplied/Storage and Handling (16.2)</a></span>]. Discard unused reconstituted solution after 3 days. Attach the supplied sticker to the vial and enter the discard date.</p>
<p>For use in neonates and infants, reconstitute with preservative-free sterile WFI [see <span class="Italics"><a href="#S5.7">Warnings and Precautions (5.7) </a></span>and <span class="Italics"><a href="#S8.4">Use in Specific Populations (8.4)</a></span>]. When reconstituted in sterile WFI, MYALEPT should be administered immediately. Unused reconstituted solution cannot be saved for later use and should be discarded.</p>
<p><span class="Bold">Reconstitution of the Lyophilized Powder</span></p>
<p>Instruct patients to follow the directions below for reconstitution of the lyophilized powder:</p>
<dl>
<dt>a)</dt>
<dd>Remove the vial containing the MYALEPT lyophilized powder from the refrigerator and allow the vial to warm to room temperature prior to use.</dd>
<dt>b)</dt>
<dd>Visually inspect the vial containing MYALEPT. The cake of lyophilized powder should be intact and white in color.</dd>
<dt>c)</dt>
<dd>Using a 3-mL syringe with a 22-gauge or smaller diameter needle withdraw 2.2 mL of sterile Bacteriostatic Water for Injection (BWFI) or preservative-free sterile Water for Injection (WFI). Do not reconstitute MYALEPT with other diluents.</dd>
<dt>d)</dt>
<dd>Inject the BWFI or WFI into the vial containing the lyophilized powder of MYALEPT, slowly injecting down the side of the vial. It is normal for some bubbles to form.</dd>
<dt>e)</dt>
<dd>Remove the needle and syringe from the vial and <span class="Bold">gently swirl</span> the contents to reconstitute. <span class="Bold">Do not shake or vigorously agitate.</span> When properly mixed, the MYALEPT reconstituted solution should be clear and free of clumps or dry powder, bubbles or foam. Do not use the solution if discolored or cloudy, or if particulate matter remains.</dd>
<dt>f)</dt>
<dd>Regarding the compatibility of MYALEPT reconstituted solution with other solutions: <dl>
<dt>•</dt>
<dd>Do not mix with, or transfer into, the contents of another vial of MYALEPT.</dd>
<dt>•</dt>
<dd>Do not add other medications, including insulin. Use a separate syringe for insulin injections.</dd>
</dl>
</dd>
</dl>
<p><span class="Bold">See the MYALEPT Instructions for Use for complete administration instructions.</span> The instructions can also be found at <span class="Italics">www.myalept.com</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Administration Instructions</h2>
<p class="First">Healthcare practitioners should instruct patients and caregivers on the proper subcutaneous injection technique with care to avoid intramuscular injection in patients with minimal subcutaneous adipose tissue. Never administer MYALEPT intravenously or intramuscularly. </p>
<p>Instruct patients to follow the recommended injection technique:</p>
<dl>
<dt>a)</dt>
<dd>Using a 1-mL syringe with a needle appropriate for subcutaneous injection, withdraw the prescribed dose of MYALEPT reconstituted solution.</dd>
<dt>b)</dt>
<dd>Remove any large air pockets or large bubbles from the filled syringe prior to administration. Some small bubbles may remain in the syringe.</dd>
<dt>c)</dt>
<dd>Administer MYALEPT into the subcutaneous tissue of the abdomen, thigh or upper arm. Advise patients to use a different injection site each day when injecting in the same region. After choosing an injection site, pinch the skin and at a 45-degree angle, inject the MYALEPT reconstituted solution subcutaneously. Avoid intramuscular injection, especially in patients with minimal subcutaneous adipose tissue. </dd>
<dt>d)</dt>
<dd>Doses exceeding 1 mL can be administered as two injections (the total daily dose divided equally) to minimize potential injection-site <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> due to injection volume. When dividing doses due to volume, doses can be administered one after the other. </dd>
</dl>
<p>Do not mix MYALEPT with insulin. Use a separate syringe for each medication. If MYALEPT and insulin are administered at the same time of day, they may be injected in the same body area using two different injection sites.</p>
<p><span class="Bold">See the MYALEPT Instructions for Use for complete administration instructions.</span> The instructions can also be found at <span class="Italics">www.myalept.com</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4	Dosage Adjustments of Medications Known to Cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h2>
<p class="First">Dosage adjustments, including possible large reductions, of insulin or insulin secretagogue (e.g., sulfonylurea) may be necessary in some patients to minimize the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> [see <span class="Italics"><a href="#S5.4">Warnings and Precautions (5.4)</a></span> and <span class="Italics"><a href="#S6.1">Adverse Reactions (6.1)</a></span>]. Closely monitor blood glucose in patients on concomitant insulin therapy, especially those on high doses, or insulin secretagogue (e.g., sulfonylurea) when treating with MYALEPT. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5	Discontinuation in Patients at Risk for <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></h2>
<p class="First">When discontinuing MYALEPT therapy in patients with risk factors for <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> (e.g., history of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>), tapering of the dose over a one-week period is recommended. During tapering, monitor triglyceride levels and consider initiating or adjusting the dose of lipid-lowering medications as needed. Signs and/or symptoms consistent with <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> should prompt an appropriate clinical evaluation. </p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">For Injection: 11.3 mg of metreleptin supplied in a vial as a sterile, white, solid, lyophilized cake (delivers 5 mg per mL of metreleptin when reconstituted with 2.2 mL of BWFI or WFI).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4	CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1	General <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span></h2>
<p class="First">MYALEPT is contraindicated in patients with general <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> not associated with congenital leptin deficiency. MYALEPT has not been shown to be effective in treating general <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, and the development of anti-metreleptin antibodies with neutralizing activity has been reported in obese patients treated with MYALEPT [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.2"></a><a name="section-4.2"></a><p></p>
<h2>4.2	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">MYALEPT is contraindicated in patients with prior severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to metreleptin or to any of the product components. Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have included <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> [see <span class="Italics"><a href="#S5.6">Warnings and Precautions (5.6)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Risk for Development of Antibodies that Neutralize Endogenous Leptin and/or MYALEPT</h2>
<p class="First">Anti-metreleptin antibodies with <span class="Italics">in vitro</span> neutralizing activity to leptin associated with adverse events consistent with loss of endogenous leptin activity and/or loss of efficacy have been identified in two patients with generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> treated with MYALEPT (severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, increases in HbA<span class="Sub">1c</span> and triglycerides), and in three patients without <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> who received MYALEPT in clinical studies (excessive <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, development of <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span> or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus). The clinical implications associated with development of anti-metreleptin antibodies with neutralizing activity are not well characterized at this time due to the small number of reports. Test for anti-metreleptin antibodies with neutralizing activity in patients who develop severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or show signs suspicious for loss of MYALEPT efficacy during treatment. Contact AstraZeneca at 1-866-216-1526 for neutralizing antibody testing of clinical samples [see<span class="Italics"><a href="#S6.2"> Adverse Reactions (6.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	<span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></h2>
<p class="First">Three cases of T-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> have been reported in the MYALEPT <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> program; all three patients had acquired generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>. Two of these patients were diagnosed with peripheral T-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> while receiving MYALEPT. Both had <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> and significant hematologic abnormalities including severe bone marrow abnormalities before the start of MYALEPT treatment. A separate case of anaplastic large cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> was reported in a patient receiving MYALEPT who did not have hematological abnormalities before treatment.</p>
<p><span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">Lymphoproliferative disorders</span>, including <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span>, have been reported in patients with acquired generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> not treated with MYALEPT. A causal relationship between MYALEPT treatment and the development and/or progression of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> has not been established. Acquired lipodystrophies are associated with <span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">autoimmune disorders</span>, and <span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">autoimmune disorders</span> are associated with an increased risk of malignancies including <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span>.</p>
<p>The benefits and risks of MYALEPT treatment should be carefully considered in patients with acquired generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> and/or those with significant hematologic abnormalities (including <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, bone marrow abnormalities, <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, and/or <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	MYALEPT REMS Program</h2>
<p class="First">MYALEPT is available only through a restricted distribution program under a REMS, called the MYALEPT REMS Program, because of the risks associated with the development of anti-metreleptin antibodies that neutralize endogenous leptin and/or MYALEPT and the risk for <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1, </a><a href="#S5.2">5.2)</a></span>].</p>
<p>Notable requirements of the MYALEPT REMS Program include the following:</p>
<dl>
<dt>•</dt>
<dd>Prescribers must be certified with the program by enrolling and completing training.</dd>
<dt>•</dt>
<dd>Pharmacies must be certified with the program and only dispense MYALEPT after receipt of the MYALEPT REMS Prescription Authorization Form for each new prescription.</dd>
</dl>
<p>Further information is available at <span class="Italics">www.myaleptrems.com</span> or 1-855-6MYALEPT.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> with Concomitant Use with Insulin and Insulin Secretagogues</h2>
<p class="First">Dosage adjustments, including possible large reductions, of insulin or insulin secretagogue (e.g., sulfonylurea) may be necessary in some patients to minimize the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> [see <span class="Italics"><a href="#S2.4">Dosage and Administration (2.4)</a></span> and <span class="Italics"><a href="#S6.1">Adverse Reactions (6.1)</a></span>]. Closely monitor blood glucose in patients on concomitant insulin therapy, especially those on high doses, or insulin secretagogue (e.g., sulfonylurea), when treating with MYALEPT.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	Autoimmunity</h2>
<p class="First">Leptin plays a role in immune system homeostasis. Acquired lipodystrophies are associated with <span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">autoimmune disorders</span> including <span class="product-label-link" type="condition" conceptid="200762" conceptname="Autoimmune hepatitis">autoimmune hepatitis</span> and <span class="product-label-link" type="condition" conceptid="433257" conceptname="Mesangiocapillary glomerulonephritis">membranoproliferative glomerulonephritis</span>. Cases of progression of <span class="product-label-link" type="condition" conceptid="200762" conceptname="Autoimmune hepatitis">autoimmune hepatitis</span> and <span class="product-label-link" type="condition" conceptid="433257" conceptname="Mesangiocapillary glomerulonephritis">membranoproliferative glomerulonephritis</span> (associated with massive <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>) were observed in some patients with acquired generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> treated with MYALEPT. A causal relationship between MYALEPT treatment and the development and/or progression of autoimmune disease has not been established. The potential benefits and risks of MYALEPT treatment should be carefully considered in patients with autoimmune disease. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">There have been reports of generalized <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> or generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>) in patients taking MYALEPT. If a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> occurs, instruct the patient to promptly seek medical advice regarding discontinuation of MYALEPT.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7	Benzyl Alcohol Toxicity</h2>
<p class="First">MYALEPT contains benzyl alcohol when reconstituted with BWFI. MYALEPT contains no preservative when reconstituted with sterile Water for Injection (WFI). Preservative-free WFI is recommended for use in neonates and infants. The preservative benzyl alcohol has been associated with serious adverse events and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in pediatric patients, particularly in neonates and premature infants [see <span class="Italics"><a href="#S8.4">Use in Specific Populations (8.4)</a></span>]. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6	ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Bold">Open-Label, Single-Arm Study</span></p>
<p>The safety of MYALEPT was evaluated in 48 patients with generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> in a single-arm, open-label study [see <span class="Italics"><a href="#S14.1">Clinical Studies (14.1)</a></span>]. The median duration of exposure in this trial was 2.7 years with a range of 3.6 months to 10.9 years. The most frequent adverse reactions are summarized in Table 2.</p>
<a name="_RefID0EMMAE"></a><table>
<caption><span>Table 2:  Adverse Reactions of 5% or Greater Incidence in Patients with Generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">Lipodystrophy</span> Receiving MYALEPT in an Open-Label, Single-Arm Study</span></caption>
<col width="32%">
<col width="14%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule"></th>
<th class="Botrule Lrule Rrule Toprule">
<span class="Bold">All Subjects</span><br><span class="Bold">N=48 (%)</span>
</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Hypoglycemic events were assessed as mild, moderate, severe, or life threatening based on the protocol specified definitions: Mild: Documentation of low plasma glucose values with no symptoms; Moderate: Presence of clinical symptoms requiring ingestion of glucose, self-alleviated; Severe: Presence of neuroglycopenic symptoms requiring assistance from others for alleviation; Life threatening: <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">Loss of consciousness</span> and/or requiring intervention by administration of intravenous glucose or intramuscular glucagon.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6 (13)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6 (13)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Decreased weight</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6 (13)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5 (10)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4 (8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4 (8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4044878" conceptname="Infection of ear">Ear infection</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4 (8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4 (8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4 (8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">Ovarian cyst</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4 (8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4 (8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3 (6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3 (6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3 (6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3 (6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3 (6)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3 (6)</p></td>
</tr>
</tbody>
</table>
<p>In patients with generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> receiving MYALEPT in this study, less common adverse reactions included injection-site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> (N=2 [4%]).</p>
<p>Six patients (13%) had 7 adverse reactions of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, 6 of which occurred in the setting of concomitant insulin use, with or without oral antihyperglycemic agents.</p>
<p>Two patients (4%) had events of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, both of whom had a medical history of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Immunogenicity</h2>
<p class="First">As with all therapeutic proteins, there is potential for immunogenicity. Anti-metreleptin antibodies were detected in 84% (36/43) of generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> patients studied in the MYALEPT trials. Total anti-metreleptin antibody titers ranged between 1:5 and 1:1,953,125. The incompleteness of the current immunogenicity database precludes understanding of the magnitude and persistence of the observed anti-drug antibody responses. Anti-metreleptin antibodies with neutralizing activity associated with adverse events consistent with loss of endogenous leptin activity and/or loss of MYALEPT efficacy were observed in 6% (2/33) of the patients with generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> tested. Adverse events reported in these two patients included severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and worsening of metabolic control (increases in HbA<span class="Sub">1c</span> and/or triglycerides). Test for anti-metreleptin antibodies with neutralizing activity in patients who develop severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or show signs suspicious for loss of MYALEPT efficacy during treatment. Contact AstraZeneca at 1-866-216-1526 for testing of clinical samples.</p>
<p>The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. The immunogenicity assays utilized in clinical trials lacked sensitivity, resulting in potential underestimation of the number of samples positive for anti-metreleptin antibodies with neutralizing activity. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to metreleptin with the incidence of antibodies to other products may be misleading.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7	DRUG INTERACTIONS</h1>
<p class="First">No formal drug interaction studies were performed.</p>
<p>Leptin is a cytokine and may have the potential to alter the formation of cytochrome P450 (CYP450) enzymes. This should be taken into account when prescribing concomitant drugs metabolized by CYP450 (e.g., oral contraceptives and drugs with a narrow therapeutic index). The effect of metreleptin on CYP450 enzymes may be clinically relevant for CYP450 substrates with narrow therapeutic index, where the dose is individually adjusted. Upon initiation or discontinuation of MYALEPT, in patients being treated with these types of agents, therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) should be performed and the individual dose of the agent adjusted as needed.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8	USE IN SPECIFIC POPULATIONS  </h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1	Pregnancy </h2>
<p class="First"><span class="Bold">Pregnancy Category C</span></p>
<p>There is a program that monitors outcomes in women exposed to MYALEPT during pregnancy. Women who become pregnant during MYALEPT treatment are encouraged to enroll. Patients or their physicians should call 1-855-6MYALEPT to enroll.</p>
<p><span class="Bold"><span class="Italics">Risk Summary</span></span></p>
<p>There are no adequate and well-controlled studies of MYALEPT in pregnant women. All pregnancies, regardless of drug exposure, have a background rate of 2% to 4% for major malformations and 15% to 20% for pregnancy loss. In a pre- and postnatal development study in mice, administration of metreleptin caused prolonged gestation and dystocia resulting in maternal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> during parturition and lower survival of offspring in the immediate postnatal period at doses starting approximately at the maximum recommended clinical dose. Because animal reproduction studies are not always predictive of human response, MYALEPT should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p><span class="Bold"><span class="Italics">Clinical Considerations</span></span></p>
<p><span class="Italics">Disease-Associated Maternal and Fetal Risk</span></p>
<p>The contribution of MYALEPT to obstetrical risks and complications is unknown compared with those already documented in the <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> patient population (e.g., <span class="product-label-link" type="condition" conceptid="4024659" conceptname="Gestational diabetes mellitus">gestational diabetes</span>, macrosomia, <span class="product-label-link" type="condition" conceptid="443700" conceptname="Eclampsia">eclampsia</span>, <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">intrauterine growth retardation</span>, intrauterine <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, and <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span>).</p>
<p><span class="Italics">Labor and Delivery</span></p>
<p>The effects of MYALEPT on labor and delivery in pregnant women are unknown. In an <span class="Italics">in vitro</span> study of human myometrial tissue exposed to a recombinant leptin, human uterine contractility was inhibited. Furthermore, prolonged gestation and dystocia were observed in animal studies with metreleptin (see below).</p>
<p><span class="Bold"><span class="Italics">Animal Data</span></span></p>
<p>Metreleptin administered to pregnant mice during the period of organogenesis was not teratogenic at doses ranging between 7- and 15-fold the maximum recommended clinical dose, based on body surface area of a 20- and 60-kg patient, respectively.</p>
<p>In a pre- and postnatal development study in mice, metreleptin administered at doses of 3, 10, and 30 mg/kg (approximately 1-, 5-, and 15-fold the clinical dose for a 60-kg subject, based on body surface area) from gestation day 6 to lactation day 21 caused prolonged gestation and dystocia at all doses, starting at approximately the maximum recommended clinical dose. Prolonged gestation resulted in the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of some females during parturition and lower survival of offspring within the immediate postnatal period. Consistent with metreleptin pharmacology, decreased maternal body weight was observed from gestation throughout lactation at all doses and resulted in reduced weight of offspring at birth, which persisted into adulthood. However, no developmental abnormalities were observed and reproductive performance of the first or second generations was not affected at any dose.</p>
<p>Placental transfer of metreleptin into the fetus was low (approximately 1%) following subcutaneous dosing.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First">It is not known if MYALEPT is present in human milk. Endogenous leptin is present in human milk. Because of the potential for serious adverse reactions  (including possible adverse reactions related to passage of anti-metreleptin antibodies) in nursing infants from MYALEPT a decision should be made whether to discontinue nursing or discontinue the drug, taking into account importance of drug to the mother [see <span class="Italics"><a href="#S6.2">Adverse Reactions (6.2) </a></span> and <span class="Italics"><a href="#S13.1">Nonclinical Toxicology (13.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4	Pediatric Use</h2>
<p class="First">The MYALEPT study included a total of 35 pediatric patients (73%) with an age range from 1 to 17 years [see <span class="Italics"><a href="#S14.1">Clinical Studies (14.1)</a></span>]. No clinically meaningful differences were observed in the efficacy and safety of MYALEPT between pediatric and adult patients.</p>
<p>MYALEPT contains benzyl alcohol when reconstituted with BWFI. MYALEPT contains no preservative when reconstituted with WFI. Preservative-free WFI is recommended for use in neonates and infants. The preservative benzyl alcohol has been associated with serious adverse events and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, particularly in pediatric patients. The "<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> syndrome" (characterized by central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> respirations, and high levels of benzyl alcohol and its metabolites found in the blood and urine) has been associated with benzyl alcohol dosages &gt;99 mg/kg/day in neonates and low-birth weight infants. Additional symptoms may include gradual neurological deterioration, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>, hematologic abnormalities, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin breakdown</span>, hepatic and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>.</p>
<p>Although normal therapeutic doses of this product deliver amounts of benzyl alcohol that are substantially lower than those reported in association with the "<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> syndrome," the minimum amount of benzyl alcohol at which toxicity may occur is not known. Premature and low-birth-weight infants, as well as patients receiving high dosages, may be more likely to develop toxicity. Practitioners administering this and other medications containing benzyl alcohol should consider the combined daily metabolic load of benzyl alcohol from all sources. When reconstituted with 2.2 mL of BWFI, MYALEPT contains 1.76 mg of benzyl alcohol per mg of metreleptin or 9 mg of benzyl alcohol per mL of reconstituted product. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5	Geriatric Use</h2>
<p class="First">Clinical trials of MYALEPT did not include sufficient numbers of subjects aged 65 and over (n=1) to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10	OVERDOSAGE</h1>
<p class="First">There were no reports of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> in the <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> clinical trial program of MYALEPT. In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, patients should be monitored and appropriate supportive treatment be initiated as dictated by the patient’s clinical status.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11	DESCRIPTION</h1>
<p class="First">MYALEPT (metreleptin) for injection is a recombinant human leptin analog for injection that binds to and activates the leptin receptor. Metreleptin (recombinant methionyl-human leptin) is produced in <span class="Italics">E. coli</span> and differs from native human leptin by the addition of a methionine residue at its amino terminus. Metreleptin is a 147-amino acid, nonglycosylated, polypeptide with one disulfide bond between Cys-97 and Cys-147 and a molecular weight of approximately 16.15 kDa.</p>
<p>MYALEPT is supplied as a sterile, white, solid, lyophilized cake containing 11.3 mg that is reconstituted with 2.2 mL of BWFI or WFI to a final formulation of 5 mg/mL metreleptin for subcutaneous injection. Inactive ingredients are: glutamic acid (1.47 mg/mL), glycine (20 mg/mL), polysorbate 20 (0.1 mg/mL), and sucrose (10 mg/mL), pH 4.25.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">Adipocytes store lipids to meet the fuel requirements of non-adipose tissues during fasting. In patients with generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>, the deficiency of adipose tissue leads to <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> and ectopic deposition of fat in non-adipose tissues such as liver and muscle, contributing to metabolic abnormalities including <span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">insulin resistance</span>. Native leptin is a hormone predominantly secreted by adipose tissue that informs the central nervous system of the status of energy stores in the body. In patients with generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>, leptin deficiency, resulting from the loss of adipose tissue, contributes to excess caloric intake, which exacerbates the metabolic abnormalities.</p>
<p>MYALEPT (metreleptin) for injection exerts its function by binding to and activating the human leptin receptor (ObR), which belongs to the Class I cytokine family of receptors that signals through the JAK/STAT transduction pathway.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2	Pharmacodynamics</h2>
<p class="First">Clinical studies in patients with generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> suggest that MYALEPT increases insulin sensitivity and reduces food intake. Improvements in insulin sensitivity and reductions in food intake are consistent with lower HbA<span class="Sub">1c</span>, fasting glucose, and fasting triglyceride values that were seen in the MYALEPT clinical trial [see <span class="Italics"><a href="#S14">Clinical Studies (14)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3	Pharmacokinetics</h2>
<p class="First">There are limited data on the pharmacokinetics of metreleptin in patients with generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>, and therefore, no formal exposure-response analysis has been performed. It should be noted that the leptin assay measures both endogenous leptin as well as exogenously administered metreleptin.</p>
<p><span class="Bold">Absorption</span></p>
<p>Peak serum leptin concentration (C<span class="Sub">max</span>) occurred approximately 4.0 to 4.3 hours after subcutaneous administration of single doses ranging from 0.1 to 0.3 mg/kg in healthy subjects. In a supportive trial in <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> patients, the median T<span class="Sub">max</span> of metreleptin was 4 hours (range: 2 to 8 hours; N=5) following single-dose administration of metreleptin.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0d714b92-11cb-4dd0-8c4e-04078db8c18b"></a><a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Bold">Distribution</span></p>
<p>In studies of healthy adult subjects, following intravenous administration of metreleptin, leptin volume of distribution was approximately 4 to 5 times plasma volume; volumes (Vz) (mean ± SD) were 370 ± 184 mL/kg, 398 ± 92 mL/kg, and 463 ± 116 mL/kg for 0.3, 1.0, and 3.0 mg/kg/day doses, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d2c050b9-ae0d-4a53-9f2e-275679cb11fa"></a><a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Bold">Metabolism and Elimination </span></p>
<p>No formal metabolism studies have been conducted with metreleptin. Nonclinical data indicate renal clearance is the major route of metreleptin elimination, with no apparent contribution of systemic metabolism or degradation. Following single subcutaneous doses of 0.01 to 0.3 mg/mL metreleptin in healthy subjects, the half-life was 3.8 to 4.7 hours. The clearance of metreleptin is expected to be delayed in the presence of leptin antibodies [see <span class="Italics"><a href="#S6.2">Adverse Reactions (6.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3a353d2e-d7de-4b2e-a65b-e7324876089b"></a><a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions</span></p>
<p>No drug interaction studies have been conducted in <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> patients [see <span class="Italics"><a href="#S7">Drug Interactions (7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9fe93d4a-a82e-4608-b8f8-536bde0d8bfc"></a><a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Bold">Specific Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9dfbcd22-cc77-4eac-bd26-022914caab02"></a><a name="section-11.3.4.1"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></p>
<p>No formal pharmacokinetic studies were conducted in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Nonclinical data indicate renal clearance is the major route of metreleptin elimination, with no apparent contribution of systemic metabolism or degradation. Hence, the pharmacokinetics of metreleptin may be altered in subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_774e95ce-2446-4c30-9e72-1f76cc65a5f7"></a><a name="section-11.3.4.2"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></span></p>
<p>No formal pharmacokinetic studies were conducted in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_88867d42-f9b5-439e-8206-cafe35dfa355"></a><a name="section-11.3.4.3"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Age, Gender, Race, Body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> Index</span></span></p>
<p>Specific clinical studies have not been conducted to assess the effect of age, gender, race, or body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index on the pharmacokinetics of metreleptin in patients with generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Two-year carcinogenicity studies in rodents have not been conducted with metreleptin. No proliferative or preneoplastic lesions were observed in mice or dogs following treatment up to six months. However, leptin is reported in the literature to promote cell proliferation <span class="Italics">in vitro</span> and <span class="product-label-link" type="condition" conceptid="4168352" conceptname="Tumor progression">tumor progression</span> in some mouse models of cancer.</p>
<p>Metreleptin was not mutagenic in the Ames bacterial mutagenicity assay or clastogenic in an <span class="Italics">in vitro</span> chromosomal aberration assay in Chinese hamster ovary cells and human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. Metreleptin was not mutagenic or clastogenic in an <span class="Italics">in vivo</span> mouse micronucleus assay.</p>
<p>In a fertility study in mice, metreleptin had no adverse effects on mating, fertility, or early embryonic development at doses ranging between 7 and 15 times the maximum recommended clinical dose based on body surface area of a 20- and 60-kg patient, respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14	CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1	Open-Label, Single-Arm Study</h2>
<p class="First">An open-label, single-arm study evaluated MYALEPT treatment in patients with congenital or acquired generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, and/or increased fasting insulin.</p>
<p><span class="Bold">Baseline Disease Characteristics and Demographics</span></p>
<p>Of the 48 patients enrolled, 32 (67%) had congenital generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> and 16 (33%) had acquired generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>. Overall, 36 (75%) patients were female, 22 (46%) were Caucasian, 10 (21%) Hispanic, and 9 (19%) Black. The median age at baseline was 15 years (range: 1 - 68 years), with 35 (73%) patients being less than 18 years of age. The median fasting leptin concentration at baseline was 0.7 ng/mL in males (range: 0.3 - 3.3 ng/mL) and 1.0 ng/mL in females (range: 0.3 - 3.3 ng/mL).</p>
<p><span class="Bold">Treatment Duration and Dosage in the Study</span></p>
<p>The median duration of MYALEPT treatment was 2.7 years (range: 3.6 months - 10.9 years). MYALEPT was administered subcutaneously either once daily or twice daily (in two equal doses). The weighted average daily dose (i.e., the average dose taking into account duration of treatment at different doses) for the 36 patients with baseline body weight greater than 40 kg was 2.6 mg for males and 4.6 mg for females during the first year of treatment, and 3.2 mg for males and 6.3 mg for females over the entire study period. For the 12 patients with baseline body weight less than 40 kg, the weighted average daily dose was 0.06 to 0.11 mg/kg (0.8-4.3 mg) over the entire study period.</p>
<p><span class="Bold">Efficacy Results</span></p>
<p>At baseline, 37 (77%) patients had HbA<span class="Sub">1c</span> values of 7% or greater, 19 (40%) had HbA<span class="Sub">1c</span> values of 9% or greater, 33 (69%) had fasting plasma glucose values of 126 mg/dL or greater, 17 (35%) had fasting triglyceride values of 500 mg/dL or greater, and 11 (23%) had fasting triglyceride values of 1000 mg/dL or greater.</p>
<p>Patients treated with MYALEPT had mean/median reductions in HbA<span class="Sub">1c</span>, fasting glucose, and triglycerides at 1 year (Table 3). The changes in HbA<span class="Sub">1c</span>, fasting glucose, and triglycerides observed at Month 4 were similar to those at 1 year. Concomitant antihyperglycemic and lipid-altering medication dosage regimens were not held constant during the study; for example, some patients treated with insulin had their dosage increased and others had large reductions or discontinuation of insulin.</p>
<a name="_RefTable_3"></a><table>
<caption><span>Table 3: Results in an Open-Label, Single-Arm Study in Patients with Generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">Lipodystrophy</span> Treated with MYALEPT (N=48)</span></caption>
<col width="31%">
<col width="5%">
<col width="18%">
<col width="37%">
<thead><tr class="First Last">
<th class="Botrule Rrule Toprule"><span class="Bold">Parameter</span></th>
<th class="Botrule Rrule Toprule"><span class="Bold">n</span></th>
<th class="Botrule Rrule Toprule"><span class="Bold">Baseline</span></th>
<th class="Botrule Toprule"><span class="Bold">Change from Baseline at Month 12</span></th>
</tr></thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top"><span class="Italics">SD = standard deviation; Q = quartile </span></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Rrule Toprule" valign="top"></td>
<td class="Botrule Rrule Toprule" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">Mean (SD)</p></td>
<td class="Botrule Toprule" align="center" valign="top"><p class="First">Mean (SD)</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"> HbA<span class="Sub">1c</span> (%)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">35</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">8.5 (2)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">−2 (1.5)</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"> Fasting Glucose (mg/dL)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">37</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">174 (85)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">−49 (75)</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Median (Q1, Q3)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">Median Change (Q1, Q3)</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"> Fasting Triglycerides (mg/dL)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">36</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">348 (176, 769)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">−184 (−643, −21)</p></td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top"></td>
<td class="Rrule" valign="top"></td>
<td class="Botrule" align="center" valign="top"><p class="First">Median Percent Change (Q1, Q3)</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"></td>
<td class="Botrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule" align="center" valign="top"><p class="First">−55 (−77, −20)%</p></td>
</tr>
</tbody>
</table>
<p>Among 28 patients with generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> who had a baseline HbA<span class="Sub">1c</span> 7% or greater and data available at Month 12, the mean (SD) baseline HbA<span class="Sub">1c</span> was 9.3 (1.5%) and the mean reduction in HbA<span class="Sub">1c</span> at Month 12 was 2.4%.</p>
<p>Among 12 patients with generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> who had a baseline triglyceride level 500 mg/dL or greater and data available at Month 12, the median baseline triglyceride level was 1527 mg/dL and the median reduction in triglycerides at Month 12 was 1117 mg/dL.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S16.1"></a><a name="section-14.1"></a><p></p>
<h2>16.1	How Supplied</h2>
<dl>
<dt>•</dt>
<dd>MYALEPT (metreleptin) for injection for subcutaneous administration is supplied in a single carton containing one vial for reconstitution (NDC 66780-310-01).</dd>
<dt>•</dt>
<dd>Each vial contains 11.3 mg metreleptin (as a sterile, white, solid, lyophilized cake) to deliver 5 mg per mL of metreleptin when reconstituted with 2.2 mL of BWFI or WFI.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="S16.2"></a><a name="section-14.2"></a><p></p>
<h2>16.2	Storage and Handling</h2>
<dl>
<dt>•</dt>
<dd>MYALEPT should be stored in the refrigerator at 36°F to 46°F (2°C to 8°C) and protected from light until preparing for use. Keep MYALEPT vials in the carton when not in use.</dd>
<dt>•</dt>
<dd>MYALEPT should not be used past the expiration date.</dd>
<dt>•</dt>
<dd>Do not freeze MYALEPT.</dd>
<dt>•</dt>
<dd>Do not use if the white lyophilized cake is discolored.</dd>
<dt>•</dt>
<dd>Use with BWFI: when MYALEPT is reconstituted with BWFI, the vial can be used for multiple doses within 3 days when stored in the refrigerator at 36°F to 46°F (2°C to 8°C) and protected from light.</dd>
<dt>•</dt>
<dd>Use with WFI: when MYALEPT is reconstituted with WFI, the vial can be used for a single dose should be administered immediately. Unused reconstituted solution cannot be saved for later use and should be discarded.</dd>
<dt>•</dt>
<dd>After reconstitution, the vials should not be frozen (below 0°C) or shaken vigorously. If the reconstituted product is inadvertently frozen, it should be thrown away.</dd>
<dt>•</dt>
<dd>After reconstitution, the mixture should be clear and colorless. Do not use if visible particulates are present in the solution.</dd>
<dt>•</dt>
<dd>Keep out of the reach of children.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17	PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved Patient Labeling <span class="Italics">(Medication Guide).</span></p>
<p><span class="Bold">Risk of Neutralizing Antibodies</span></p>
<p>Advise patients that neutralizing antibodies may result in loss in activity of endogenous leptin or loss of efficacy of MYALEPT. Advise patients on symptoms or signs that would warrant antibody testing [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span>  and <span class="Italics"><a href="http://file:///C:/WINDOWS/TEMP/S">Adverse Reactions (6.2)</a></span>].</p>
<p><span class="Bold">Risk of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></span></p>
<p>Advise patients that <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> has been reported in patients both treated and not treated with MYALEPT. Advise patients on symptoms or signs that indicate changes in hematologic status and the importance of routine laboratory assessments and physician monitoring [see <span class="Italics"><a href="#S5.2">Warnings and Precautions (5.2)</a></span>].</p>
<p><span class="Bold">Risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></span></p>
<p>Advise patients that the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> is increased when MYALEPT is used in combination with insulin or an insulin secretagogue (e.g., sulfonylurea). Explain the symptoms, treatment, and conditions that predispose to development of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> to the patient. Advise patients who are taking concomitant insulin, especially those on high doses, or an insulin secretagogue, to closely monitor blood glucose. <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> management should be reviewed and reinforced when initiating MYALEPT therapy, particularly when concomitantly administered with insulin or an insulin secretagogue [see <span class="Italics"><a href="#S5.4">Warnings and Precautions (5.4)</a></span>].</p>
<p><span class="Bold">Risk of Autoimmune Disease</span></p>
<p>Advise patients that worsening of autoimmune disease has been reported during the clinical study of MYALEPT. Advise patients with a history of autoimmune disease on symptoms or signs that indicate exacerbation of underlying autoimmune disease and the importance of routine laboratory assessments and physician monitoring [see <span class="Italics"><a href="#S5.5">Warnings and Precautions (5.5)</a></span>].</p>
<p><span class="Bold">Risk of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></p>
<p>Inform patients that <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been reported during use of MYALEPT. If symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> occur, patients should seek medical advice [see <span class="Italics"><a href="#S5.6">Warnings and Precautions (5.6)</a></span>].</p>
<p><span class="Bold">Nursing Mothers</span></p>
<p>Advise nursing mothers that breastfeeding is not recommended with MYALEPT use [see <span class="Italics"><a href="#S8.3">Use in Specific Populations (8.3)</a></span>].</p>
<p><span class="Bold">Instructions</span></p>
<dl>
<dt>•</dt>
<dd>Inform patients that each vial of MYALEPT requires reconstitution with BWFI or preservative-free WFI, and administration as subcutaneous injection using a syringe and needle. Injections can be given at any time of the day, with or without meals.</dd>
<dt>•</dt>
<dd>Patients and caregivers should receive proper training in how to prepare and administer the correct dose of MYALEPT prior to self-administration. The first dose of MYALEPT should be administered by the patient or caregiver under the supervision of a qualified healthcare professional.</dd>
<dt>•</dt>
<dd>Advise patients on injection technique, dosing regimen, and the importance of proper storage of MYALEPT. Care should be taken to avoid intramuscular injection, especially in patients with minimal subcutaneous adipose tissue.</dd>
<dt>•</dt>
<dd>Advise patients to read the Instructions for Use for complete administration instructions. The MYALEPT Medication Guide and Instructions for Use should be reviewed before starting therapy and each time the prescription is refilled.</dd>
<dt>•</dt>
<dd>When discontinuing MYALEPT in patients with a history of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and/or severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, instruct patients to taper their dose over a one-week period. Advise patients that additional monitoring of triglyceride levels and possible initiation or dose adjustment of lipid-lowering medications may be considered [see <span class="Italics"><a href="#S2.5">Dosage and Administration (2.5)</a></span>].</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cdc07a27-d60b-441f-8882-d42e8642f676"></a><a name="section-16"></a><p></p>
<p class="First">Manufactured for:<br>Amylin Pharmaceuticals, LLC</p>
<p>Wilmington, DE 19850</p>
<p>Distributed by:</p>
<p>AstraZeneca Pharmaceuticals LP</p>
<p>Wilmington, DE 19850</p>
<p>MYALEPT is a trademark of the AstraZeneca group of companies.</p>
<p>1334229-XX</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="ID_05883793-e27b-44ee-b566-12c7a5f32ec2"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Medication Guide</span></p>
<p>MYALEPT<span class="Sup">™</span> (MAI-uh-lept) <br>(metreleptin) for injection<br>for subcutaneous use</p>
<p>Read this Medication Guide that comes with MYALEPT before you start using it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your healthcare provider about your medical condition or your treatment.</p>
<p><span class="Bold">What is the most important information I should know about MYALEPT?  </span></p>
<p><span class="Bold">MYALEPT may cause serious side effects, including:</span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">risk for loss of endogenous leptin activity or loss of MYALEPT efficacy due to neutralizing antibodies.</span><br>Some people who use MYALEPT make antibodies in their blood that may reduce how well the leptin in your body (endogenous) works or how well MYALEPT works. Side effects may include:<dl>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></dd>
<dt>∘</dt>
<dd>problems with blood sugar, including <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></dd>
<dt>∘</dt>
<dd>an increase in the amount of fat in your blood (triglycerides)</dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (a type of blood cancer).</span> There may be an increased risk of getting <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> when you use MYALEPT.</dd>
</dl>
<p>MYALEPT is only available through a restricted program called the MYALEPT Risk Evaluation and Mitigation Strategy (REMS) Program. For more information about the MYALEPT REMS Program go to <span class="Italics">www.myaleptrems.com</span> or call 1-855-6MYALEPT.</p>
<p><span class="Bold">What is MYALEPT?</span></p>
<p>MYALEPT is a prescription medicine used with a diet recommended by your healthcare provider to treat problems caused by not having enough leptin in your body (leptin deficiency) in people with congenital or acquired generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>.</p>
<dl>
<dt>•</dt>
<dd>It is not known if MYALEPT is safe and effective when used:<dl>
<dt>∘</dt>
<dd>to treat problems (complications) caused by partial <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span></dd>
<dt>∘</dt>
<dd>to treat liver disease, including non-alcoholic steatohepatitis (NASH)</dd>
</dl>
</dd>
<dt>•</dt>
<dd>MYALEPT should not be used to treat:<dl>
<dt>∘</dt>
<dd>people with HIV-related <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span></dd>
<dt>∘</dt>
<dd>people with metabolic disease, including <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus and <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, without signs or symptoms of congenital or acquired generalized <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span></dd>
</dl>
</dd>
</dl>
<p><span class="Bold">Who should not use MYALEPT?</span></p>
<p><span class="Bold">Do not use MYALEPT if you:</span></p>
<dl>
<dt>•</dt>
<dd>have general <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> that is not caused by a congenital leptin deficiency.</dd>
<dt>•</dt>
<dd>are allergic to metreleptin or any of the ingredients in MYALEPT. See the end of this Medication Guide for a complete list of ingredients in MYALEPT.<br>Talk to your healthcare provider right away if you have any symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> including a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> (<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>).<br>Symptoms of a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> may include: <dl>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, lips, tongue, or throat</dd>
<dt>∘</dt>
<dd>problems breathing or swallowing</dd>
<dt>∘</dt>
<dd>severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> or feeling dizzy</dd>
<dt>∘</dt>
<dd>very rapid heartbeat</dd>
</dl>
</dd>
</dl>
<p><span class="Bold">What should I tell my healthcare provider before using MYALEPT?</span></p>
<p><span class="Bold">Before using MYALEPT, tell your healthcare provider if you:</span></p>
<dl>
<dt>•</dt>
<dd>have or have had problems with your blood cells including low blood cell counts, especially white blood cells</dd>
<dt>•</dt>
<dd>have or have had problems with your bone marrow</dd>
<dt>•</dt>
<dd>have or have had <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">swollen lymph nodes</span> (<span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>)</dd>
<dt>•</dt>
<dd>have or have had <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span></dd>
<dt>•</dt>
<dd>use insulin or a sulfonylurea</dd>
<dt>•</dt>
<dd>have or have had problems with your immune system (autoimmune disease)</dd>
<dt>•</dt>
<dd>have or have had problems with your pancreas (<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>)</dd>
<dt>•</dt>
<dd>have high blood triglyceride levels</dd>
<dt>•</dt>
<dd>have any other medical conditions</dd>
<dt>•</dt>
<dd>are pregnant or plan to become pregnant.  It is not known if MYALEPT will harm your unborn baby<dl>
<dt>∘</dt>
<dd>If you become pregnant while using MYALEPT, talk to your healthcare provider about registering with a program to collect information about the outcomes of moms and babies exposed to MYALEPT during pregnancy. You can enroll in the MYALEPT program by calling 1-855-6MYALEPT.</dd>
</dl>
</dd>
<dt>•</dt>
<dd>are breastfeeding or plan to breastfeed. It is not known if MYALEPT passes into your breast milk. You and your healthcare provider should decide if you will take MYALEPT or breastfeed. You should not do both.</dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p>
<p>Know the medicines you take. Keep a list of them with you to show your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I use MYALEPT?</span></p>
<p>See the<span class="Bold"> Instructions for Use </span>that come with MYALEPT for detailed instructions on using MYALEPT the right way. </p>
<dl>
<dt>•</dt>
<dd>Use MYALEPT exactly as your healthcare provider tells you to.</dd>
<dt>•</dt>
<dd>Your healthcare provider will tell you how much MYALEPT to use and when to use it. <span class="Bold">Do not </span>change your dose unless your healthcare provider tells you to. <dl>
<dt>∘</dt>
<dd>
<span class="Bold">Do not</span> suddenly stop using MYALEPT. Stopping MYALEPT suddenly may cause a serious problem with your pancreas (<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>) and very high triglycerides.</dd>
<dt>∘</dt>
<dd>If your healthcare provider decides that you should stop using MYALEPT, your healthcare provider should slowly decrease your dose (taper) over 1 week.</dd>
</dl>
</dd>
<dt>•</dt>
<dd>MYALEPT is injected 1 time a day at the same time each day.</dd>
<dt>•</dt>
<dd>MYALEPT can be used with or without food.</dd>
<dt>•</dt>
<dd>If you miss a dose of MYALEPT, take it as soon as you remember. Take your regular dose the next day at your normal time. <span class="Bold">Do not </span>take more than your regular daily dose in a single day. <span class="Bold">Do not </span>take an extra dose or increase the amount of your dose to make up for a missed dose.</dd>
<dt>•</dt>
<dd>
<span class="Bold">Do not</span> mix MYALEPT and insulin in the same syringe or vial. Although MYALEPT and insulin doses may be given at the same time, <span class="Bold">do not</span> inject MYALEPT and insulin in the same injection site.</dd>
<dt>•</dt>
<dd>When MYALEPT is used in newborns or infants, your healthcare provider will tell you if MYALEPT should be mixed with a liquid called sterile water for injection (WFI) (preservative-free). For older children and adults, bacteriostatic water for injection (BWFI) may be used.</dd>
<dt>•</dt>
<dd>MYALEPT is given as an injection under the skin (subcutaneous) of your stomach (abdomen), thigh, or upper arm. <span class="Bold">Do not inject MYALEPT into a vein or muscle.</span>
</dd>
</dl>
<p><span class="Bold">What are the possible side effects of MYALEPT?</span></p>
<p><span class="Bold">MYALEPT can cause serious side effects, including:  </span></p>
<dl>
<dt>•</dt>
<dd>See<span class="Bold"> "What is the most important information I should know about MYALEPT?"</span>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>). </span>You may get low blood sugar if you use MYALEPT with another medicine that can cause low blood sugar, such as insulin or sulfonylurea. The dose of your insulin or sulfonylurea may need to be lowered while you use MYALEPT. Signs and symptoms of low blood sugar may include: </dd>
</dl>
<table>
<col width="26%">
<col width="25%">
<tbody class="Headless"><tr class="First Last Toprule">
<td valign="top"><dl>
<dt> </dt>
<dd><dl>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shakiness</span></dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span></dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></dd>
</dl></dd>
</dl></td>
<td valign="top"><dl>
<dt> </dt>
<dd><dl>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">hunger</span></dd>
<dt>∘</dt>
<dd>fast heart beat</dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">feeling jittery</span></dd>
</dl></dd>
</dl></td>
</tr></tbody>
</table>
<p><span class="Bold">Talk with your healthcare provider about how to recognize and treat low blood sugar.</span> Make sure that your family and other people around you a lot know how to recognize and treat low blood sugar.</p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">autoimmunity.</span> People who have or have had certain problems with their immune system (autoimmune disease) may have worsening of their symptoms with MYALEPT. Talk to your healthcare provider about what symptoms you should watch for that would warrant further testing. </dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>).</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> can happen in people who use MYALEPT. Talk to your healthcare provider right away if you have any symptom of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. See "<span class="Bold">Who should not take MYALEPT?</span>?</dd>
<dt>•</dt>
<dd>
<span class="Bold">benzyl alcohol toxicity.</span> Serious side effects including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have happened in newborns or infants who have received the preservative benzyl alcohol. MYALEPT, when mixed with a liquid called bacteriostatic water for injection (BWFI), contains benzyl alcohol. MYALEPT, when mixed with a liquid called sterile water for injection (WFI) (preservative-free), contains no benzyl alcohol. When MYALEPT is used in newborns or infants, MYALEPT should be mixed with sterile water for injection (WFI).</dd>
</dl>
<p><span class="Bold">The most common side effects of MYALEPT include: </span></p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
<dt>•</dt>
<dd>low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>)</dd>
<dt>•</dt>
<dd>decreased weight</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></dd>
</dl>
<p>Talk to your healthcare provider about any side effect that bothers you or that does not go away.</p>
<p>These are not all the side effects with MYALEPT. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store MYALEPT?</span></p>
<dl>
<dt>•</dt>
<dd>Store MYALEPT in the refrigerator between 36°F to 46°F (2°C to 8°C).</dd>
<dt>•</dt>
<dd>KEEP MYALEPT vials in their carton and out of the light.</dd>
<dt>•</dt>
<dd>
<span class="Bold">Do not</span> freeze MYALEPT.</dd>
<dt>•</dt>
<dd>
<span class="Bold">Do not</span> use MYALEPT past the expiration date printed on the vial.</dd>
<dt>•</dt>
<dd>
<span class="Bold">Do not</span> use MYALEPT if the white powder in the vial is discolored.</dd>
<dt>•</dt>
<dd>After mixing, the MYALEPT liquid in the vial should be clear and colorless. <span class="Bold">Do not</span> use MYALEPT if it is colored or cloudy, or has any lumps or particles in it. Throw the vial away and get a new one.</dd>
<dt>•</dt>
<dd>After mixing, <span class="Bold">do not</span> freeze or shake MYALEPT.</dd>
<dt>•</dt>
<dd>
<span class="Bold">MYALEPT mixed with BWFI:</span><dl>
<dt>∘</dt>
<dd>MYALEPT can be used for more than 1 dose for up to 3 days when stored in the refrigerator between 36°F to 46°F (2°C to 8°C) and out of the light. Throw away any unused MYALEPT after 3 days.</dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">MYALEPT mixed with WFI:</span><dl>
<dt>∘</dt>
<dd>Should be used right away. Throw away any unused MYALEPT, it cannot be saved for later use.</dd>
</dl>
</dd>
</dl>
<p><span class="Bold">Keep MYALEPT and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of MYALEPT</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use MYALEPT for a condition for which it was not prescribed. Do not give MYALEPT to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about MYALEPT. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about MYALEPT that is written for health professionals.</p>
<p>For more information about MYALEPT, go to <span class="Italics">www.myalept.com</span> or call MYALEPT Customer Service at 1-855-6MYALEPT.</p>
<p><span class="Bold">What are the ingredients in MYALEPT?</span></p>
<p><span class="Bold">Active Ingredient:</span>  metreleptin</p>
<p><span class="Bold">Inactive Ingredients:  </span>glutamic acid, glycine, sucrose, and polysorbate 20</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>MYALEPT is a trademark of the AstraZeneca group of companies.</p>
<p>Manufactured for:<br>Amylin Pharmaceuticals, LLC</p>
<p>Wilmington, DE 19850</p>
<p>Distributed by:</p>
<p>AstraZeneca Pharmaceuticals LP</p>
<p>Wilmington, DE 19850</p>
<dl>
<dt> </dt>
<dd>1334328-xx	Approved:  June 2014</dd>
</dl>
</div>
<div class="Section" data-sectionCode="59845-8">
<a name="ifu"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">Instructions for Use</span><br>MYALEPT<span class="Sup">™ </span>(MAI-uh-lept)<br>(metreleptin) for injection<br>Vial</p>
<dl>
<dt>•</dt>
<dd><span class="Bold">A healthcare provider should show you how to inject MYALEPT before you use it for the first time. A healthcare provider should also watch you inject your MYALEPT dose the first time you inject it.</span></dd>
<dt>•</dt>
<dd>
<span class="Bold">Do not</span> inject MYALEPT until your healthcare provider has shown you the right way to inject it. If you have questions or do not understand the instructions, talk to your healthcare provider or pharmacist.</dd>
<dt>•</dt>
<dd>MYALEPT is <span class="Bold">only</span> for use under the skin (subcutaneous).</dd>
<dt>•</dt>
<dd>
<span class="Bold">Do not</span> share your MYALEPT needles with another person. You may give an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to them, or get an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> from them.</dd>
</dl>
<p><span class="Bold">This Instructions for Use is divided into 6 steps:</span></p>
<p><span class="Bold">Step 1: Getting started</span></p>
<p><span class="Bold">Step 2: Filling the 3 mL syringe with 2.2 mL of liquid</span></p>
<p><span class="Bold">Step 3: Preparing MYALEPT</span></p>
<p><span class="Bold">Step 4: Filling the 1 mL syringe used for injecting MYALEPT</span></p>
<p><span class="Bold">Step 5: Injecting MYALEPT</span></p>
<p><span class="Bold">Step 6: Disposing of used needles and syringes</span></p>
<p>If at any time during these steps you have questions:</p>
<dl>
<dt>•</dt>
<dd>See the "Common Questions" tab</dd>
<dt>•</dt>
<dd>Call 1-855-6MYALEPT</dd>
<dt>•</dt>
<dd>
<span class="Bold">Visit</span><span class="Bold">www.MYALEPT.com</span>
</dd>
</dl>
<p><span class="Bold">Supplies you will need to give your MYALEPT (see Figure A).</span></p>
<p><span class="Bold">Make sure you have all the supplies listed below BEFORE using MYALEPT.</span></p>
<p>You can get these supplies with a prescription from your healthcare provider, from a retail or hospital pharmacy, or the specialty pharmacy that distributes MYALEPT.</p>
<dl>
<dt>•</dt>
<dd>a vial with MYALEPT powder</dd>
<dt>•</dt>
<dd>a vial with liquid for mixing MYALEPT<dl>
<dt>∘</dt>
<dd>Sterile water for injection should be used in newborns and infants</dd>
<dt>∘</dt>
<dd>Bacteriostatic water for injection should be used for older children and adults</dd>
</dl>
</dd>
<dt>•</dt>
<dd>a 3 mL syringe with a longer needle (22 G × 1″) for mixing MYALEPT</dd>
<dt>•</dt>
<dd>a 1 mL syringe with a shorter needle (26 G × ⅜″) for injecting MYALEPT</dd>
<dt>•</dt>
<dd>2 alcohol swabs</dd>
<dt>•</dt>
<dd>1 sharps container for throwing away used needles and syringes. See "<span class="Bold">Disposing of used needles and syringes</span>" at the end of these instructions.</dd>
</dl>
<div class="Figure">
<a name="id1448"></a><img alt="what you need" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-01.jpg">
</div>
<span class="Bold"><div class="Figure">
<a name="id1449"></a><img alt="Figure A - picture of alcohol wipes and sharps disposal container" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-02.jpg">
</div></span><p>Figure A</p>
<p><span class="Bold">How to read a syringe:</span></p>
<p><span class="Bold">The 3 mL syringe has a longer needle (see Figure B).</span></p>
<p><span class="Bold">The 3 mL syringe is the syringe you will use to mix MYALEPT. </span>Always fill the 3 mL syringe with 2.2 mL of liquid. <span class="Bold">Do not</span> inject yourself with the 3 mL syringe.</p>
<div class="Figure">
<a name="id1463"></a><img alt="Other supplies" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-03.jpg">
</div>
<p>Figure B</p>
<p><span class="Bold">The 1 mL syringe has a shorter needle (see Figure C).</span></p>
<p>This 1 mL syringe is the syringe you will use to inject MYALEPT. <span class="Bold">Only use the 1 mL syringe to inject your dose of MYALEPT.</span></p>
<div class="Figure">
<a name="id1474"></a><img alt="Other supplies" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-04.jpg">
</div>
<p>Figure C</p>
<p><span class="Bold">Step 1: Getting Started</span></p>
<p>Your dose of MYALEPT may change over time, depending on how MYALEPT works for you. So it is important to keep track of your dose. On the line below, write down your dose in mL and the date. Be sure to keep this up-to-date if your dose changes:</p>
<table>
<col width="23%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Toprule" align="center" valign="top">
<a name="id1485"></a><img alt="keep track of dose" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-05.jpg">
</td></tr></tbody>
</table>
<dl>
<dt>•</dt>
<dd>Take 1 MYALEPT vial out of the refrigerator 10 minutes before you plan to inject to allow it to reach room temperature. </dd>
<dt>•</dt>
<dd>Set 1 vial with the liquid you will need to mix MYALEPT on your work surface. </dd>
<dt>•</dt>
<dd>Check the powder in the MYALEPT vial. It should be white. <span class="Bold">Do not </span>use MYALEPT if the powder is discolored. Throw it away and get a new one. </dd>
<dt>•</dt>
<dd>Check the expiration date printed on the MYALEPT vial. <span class="Bold">Do not </span>use MYALEPT past the expiration date printed on the vial <span class="Bold">(see Figure D)</span>.</dd>
</dl>
<div class="Figure">
<a name="id1498"></a><img alt="check for expiration date" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-06.jpg">
</div>
<p>Figure D</p>
<p><span class="Bold">For this step, you will need:</span></p>
<table>
<col width="27%">
<col width="18%">
<col width="21%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Toprule" valign="top"><p class="First">Vial with liquid for mixing<br>a dose of MYALEPT<br><a name="id1512"></a><img alt="water for injection" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-07.jpg"></p></td>
<td class="Botrule Toprule" valign="top"><p class="First">Vial with powder<br>(MYALEPT) <br><a name="id1516"></a><img alt="myalept powder" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-08.jpg"></p></td>
<td class="Botrule Toprule" valign="top"><p class="First"> Alcohol wipes <br><a name="id1519"></a><img alt="alcohol wipes" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-09.jpg"></p></td>
</tr></tbody>
</table>
<table>
<col width="29%">
<col width="30%">
<col width="27%">
<col width="29%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Toprule" valign="top"><p class="First"><a name="id1528"></a><img alt="wash hands" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-10.jpg"> Wash your hands with soap and water. </p></td>
<td class="Botrule Toprule" valign="top"><p class="First"><a name="id1530"></a><img alt="alcohol swabs" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-11.jpg"> Remove 2 alcohol wipes from their wrappers.  <br>Place the wipes on their wrappers to keep them clean.</p></td>
<td class="Botrule Toprule" valign="top">
<a name="id1534"></a><img alt="remove vial caps" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-12.jpg"><p class="First">Use your thumb to remove the caps from the vials. </p>
</td>
<td class="Botrule Toprule" valign="top">
<a name="id1536"></a><img alt="clean bottles with alcohol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-13.jpg"><p class="First">Clean the tops of the vials with one of the alcohol wipes. </p>
</td>
</tr></tbody>
</table>
<p><span class="Bold">STEP 2: Filling the 3 mL syringe (used to mix MYALEPT) with 2.2 mL of liquid</span></p>
<p><span class="Bold">For this step, you will need: </span></p>
<table>
<col width="59%">
<col width="17%">
<col width="26%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Toprule" align="center" valign="top">
<p class="First"> A 3 mL syringe (with longer needle) used to mix MYALEPT </p>
<a name="id1548"></a><img alt="mixing syringe" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-14.jpg">
</td>
<td class="Botrule Toprule" align="center" valign="top">
<p class="First"> Vial with liquid<br>(from Step 1) </p>
<a name="id1551"></a><img alt="water for injection" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-15.jpg">
</td>
<td class="Botrule Toprule" align="center" valign="top">
<p class="First"> Sharps disposal container </p>
<a name="id1553"></a><img alt="Sharps disposal container" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-16.jpg">
</td>
</tr></tbody>
</table>
<table>
<col width="5%">
<col width="73%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Toprule" align="center" valign="top">
<a name="id1560"></a><img alt="step 2a" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-17.jpg">
</td>
<td class="Botrule Toprule" valign="top"><p class="First">Take the 3 mL syringe out of the plastic wrapper. Always use a new syringe. </p></td>
</tr></tbody>
</table>
<table>
<col width="30%">
<col width="48%">
<col width="37%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Toprule" valign="top">
<a name="id1569"></a><img alt="pull cover" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-18.jpg"><p class="First">Pull the needle cover straight off. <span class="Bold">Do not</span> twist the needle when removing the cover.</p>
<p>Put the needle cover in the sharps disposal container. </p>
</td>
<td class="Botrule Toprule" valign="top">
<a name="id1573"></a><img alt="pull down plunger" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-19.jpg"><p class="First">Pull down the plunger to fill the syringe with air. </p>
<p><br>You <span class="Bold">must first </span>fill the syringe with air and put that air into the vial to make it easier to later fill the syringe with liquid.</p>
</td>
<td class="Botrule Toprule" valign="top">
<a name="id1578"></a><img alt="line up with black rim" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-20.jpg"><p class="First">Line up the top rim of the plunger with the black 2.2 mL line. </p>
</td>
</tr></tbody>
</table>
<table>
<col width="68%">
<col width="47%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Toprule" valign="top">
<a name="id1587"></a><img alt="set vial on surface" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-21.jpg"><p class="First">Set the vial with the liquid on the work surface. Insert the needle into the top of the vial. </p>
</td>
<td class="Botrule Toprule" valign="top">
<a name="id1589"></a><img alt="push needle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-22.jpg"><p class="First">Push the plunger down all the way to fill the vial with air. </p>
</td>
</tr></tbody>
</table>
<table>
<col width="29%">
<col width="32%">
<col width="28%">
<col width="26%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Toprule" valign="top">
<p class="First"><a name="id1600"></a><img alt="turn vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-23.jpg"> With the needle still in the vial, turn the vial and syringe upside down.<br></p>
<p>Keep the whole needle in the liquid. </p>
</td>
<td class="Botrule Toprule" valign="top">
<a name="id1603"></a><img alt="pull plunger" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-24.jpg"><p class="First">Pull down the plunger until the top rim of the plunger lines up with the black 2.2 mL line. </p>
</td>
<td class="Botrule Toprule" valign="top">
<p class="First"><a name="id1605"></a><img alt="check for air pockets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-25.jpg"> Check to see if there is an air pocket in the syringe.<br></p>
<p>If you see an air pocket, tap the side of the syringe to move the air pocket to the top of the syringe. </p>
</td>
<td class="Botrule Toprule" valign="top">
<a name="id1608"></a><img alt="push plunger" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-26.jpg"><p class="First">Push the plunger up to remove the air pocket.<br><br><span class="Bold">You must remove the air pocket to be able to fill the syringe with 2.2 mL of liquid.</span></p>
</td>
</tr></tbody>
</table>
<p><br><span class="Bold">Tip: You will always fill the 3 mL syringe with 2.2 mL of liquid.</span></p>
<table>
<col width="28%">
<col width="26%">
<col width="32%">
<col width="29%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Toprule" valign="top">
<a name="id1623"></a><img alt="check for airbubbles" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-27.jpg"><p class="First">Check to see if there are large air bubbles in the syringe.</p>
<p><br>If you see large air bubbles in the syringe, tap the syringe to move the air bubbles to the top.<br></p>
<p>If there are a few small bubbles left, that is okay. </p>
</td>
<td class="Botrule Toprule" valign="top">
<a name="id1627"></a><img alt="push plunger" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-28.jpg"><p class="First">Push the plunger up to remove as many large air bubbles as you can. </p>
</td>
<td class="Botrule Toprule" valign="top">
<a name="id1629"></a><img alt="pull plunger" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-29.jpg"><p class="First">Pull down the plunger so the top rim of the plunger lines up with the black 2.2 mL line.<br> Keep the whole needle in the liquid. </p>
</td>
<td class="Botrule Toprule" valign="top">
<a name="id1632"></a><img alt="remove from vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-30.jpg"><p class="First">Remove the needle from the vial. Be careful not to move the plunger.<br></p>
<p>Keep the syringe in your hand. <span class="Bold">Do not</span> set it down.<br></p>
<p>For instructions on how to discard the used vial of liquid, read the carton that contained those vials.</p>
</td>
</tr></tbody>
</table>
<p><br><span class="Bold">STEP 3: Preparing MYALEPT</span></p>
<p><span class="Bold">Note: If you already mixed your MYALEPT before today, go to “Using a vial of mixed MYALEPT? at the end of this step. </span></p>
<p><span class="Bold">Option 1: Mixing a new vial of MYALEPT:</span></p>
<p><span class="Bold">For this step, you will need:</span></p>
<table>
<col width="57%">
<col width="34%">
<col width="25%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Toprule" valign="top"><p class="First">The 3 mL syringe filled with 2.2 mL of liquid (from Step 2) <a name="id1653"></a><img alt="filled syringe" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-31.jpg"></p></td>
<td class="Botrule Toprule" valign="top"><p class="First">Vial with powder (from Step 1) <a name="id1655"></a><img alt="powder vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-32.jpg"></p></td>
<td class="Botrule Toprule" align="center" valign="top">
<p class="First">Sharps disposal container </p>
<a name="id1657"></a><img alt="Sharps disposal container" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-33.jpg">
</td>
</tr></tbody>
</table>
<table>
<col width="38%">
<col width="29%">
<col width="22%">
<col width="27%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="top">
<a name="id1666"></a><img alt="set the vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-34.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id1668"></a><img alt="tilt the vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-35.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id1670"></a><img alt="push plunger" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-36.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id1672"></a><img alt="add the liquid" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-37.jpg">
</td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">Set the vial with the MYALEPT powder on the work surface. Insert the needle straight down into the center of the vial. </p></td>
<td class="Botrule" valign="top"><p class="First">Then tilt the vial so that the tip of the needle is pointing toward the inside wall of the vial. </p></td>
<td class="Botrule" valign="top">
<p class="First">With your thumb, <span class="Bold">slowly </span>push the plunger down all the way. </p>
<p>The liquid should go down the inside wall of the vial.</p>
</td>
<td class="Botrule" valign="top">
<p class="First"><span class="Bold">Make sure you add the liquid slowly so that bubbles do not form in the vial.</span></p>
<p><br>No liquid should be left in the syringe.</p>
</td>
</tr>
</tbody>
</table>
<table>
<col width="36%">
<col width="39%">
<col width="40%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="top">
<a name="id1692"></a><img alt="remove the needle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-38.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id1694"></a><img alt="mix powder and liquid" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-39.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id1696"></a><img alt="mixed vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-40.jpg">
</td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top">
<p class="First">While keeping the plunger all the way down, take the needle out of the vial. <br></p>
<p>Throw away the syringe with the needle still attached into your sharps disposal container.</p>
<p><br><span class="Bold">Do not</span> recap the needle. Recapping the needle can lead to a needlestick injury. </p>
</td>
<td class="Botrule" valign="top"><p class="First">To mix the powder and liquid, <span class="Bold">move the vial gently in a circle </span>(swirl) until the liquid is clear. Do not shake the vial. </p></td>
<td class="Botrule" valign="top"><p class="First">When the medicine is mixed well, the liquid should be clear. You should not see any clumps, powder, bubbles, or foam. </p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Tip: If your vial of MYALEPT is not mixed well, go back to Step 3c.</span><br><span class="Bold"> Note: Go to Step 4 if you just mixed a new vial of MYALEPT.</span></p>
<p><span class="Bold">Option 2: Using a vial of mixed MYALEPT:</span></p>
<p><span class="Bold">Note: For newborns or infants using MYALEPT, throw away any unused mixed MYALEPT right away. Do not store it for reuse.</span></p>
<p><span class="Bold">For this step, you will need:</span></p>
<table>
<col width="28%">
<col width="16%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Vial of mixed MYALEPT</span></p>
<a name="id1721"></a><img alt="mixed vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-41.jpg">
</td>
<td class="Botrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Alcohol wipes</span></p>
<a name="id1724"></a><img alt="alcohol wipes" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-42.jpg">
</td>
</tr></tbody>
</table>
<p><span class="Bold">Choose a clean, flat work surface large enough to let you prepare the medicine.</span></p>
<table>
<col width="30%">
<col width="33%">
<col width="26%">
<col width="27%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="top">
<a name="id1735"></a><img alt="take mixed vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-43.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id1737"></a><img alt="set vial on surface" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-44.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id1739"></a><img alt="wash hands" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-45.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id1741"></a><img alt="remove wipes" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-46.jpg">
</td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First"> Take 1 vial of mixed MYALEPT out of the refrigerator.<br><br>Only MYALEPT mixed with bacteriostatic water for injection can be stored for reuse.<br><br>You must use the vial within 2 days after the day the medicine was mixed. </p></td>
<td class="Botrule" valign="top"><p class="First">Set the vial of mixed MYALEPT on the work surface for 10 to 15 minutes so that it comes to room temperature. </p></td>
<td class="Botrule" valign="top"><p class="First">Wash your hands with soap and water. </p></td>
<td class="Botrule" valign="top"><p class="First">Remove 2 alcohol wipes from their wrappers.<br><br> Place the wipes on their wrappers to keep them clean. </p></td>
</tr>
</tbody>
</table>
<table>
<col width="38%">
<col width="77%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Toprule" valign="top">
<a name="id1759"></a><img alt="clean vial top" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-47.jpg"><p class="First">Clean the top of the vial with the alcohol wipe. </p>
</td>
<td class="Botrule Toprule" valign="top">
<a name="id1761"></a><img alt="check mixed medicine" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-48.jpg"><p class="First">Check that the MYALEPT is mixed well and is clear. You should not see any clumps, powder, bubbles, or foam. <br><br>If you see clumps, powder, bubbles, or foam, throw away the vial in the sharps disposal container. </p>
</td>
</tr></tbody>
</table>
<p><span class="Bold">Important:</span></p>
<table>
<col width="89%">
<col width="27%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Toprule" valign="top"><p class="First">Go to Step 4 (page xx) to inject your dose of MYALEPT. Do not mix any liquid or mixed medicine from another vial with the vial you just cleaned.</p></td>
<td class="Botrule Toprule" align="center" valign="top">
<a name="id1773"></a><img alt="step 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-49.jpg">
</td>
</tr></tbody>
</table>
<p><span class="Bold">STEP 4: Filling the 1 mL syringe used for injecting MYALEPT</span></p>
<p><span class="Bold">For this step, you will need:</span></p>
<table>
<col width="61%">
<col width="27%">
<col width="17%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Toprule" valign="top">
<p class="First">A 1 mL syringe (with shorter needle) used to inject MYALEPT</p>
<br><a name="id1786"></a><img alt="injecting syringe" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-50.jpg">
</td>
<td class="Botrule Toprule" valign="top"><p class="First">Vial of mixed MYALEPT<br>(from Step 3) <br><a name="id1790"></a><img alt="mixed vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-51.jpg"></p></td>
<td class="Botrule Toprule" valign="top"><p class="First"> Sharps disposal<br>container <br><a name="id1794"></a><img alt="Sharps disposal container" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-52.jpg"></p></td>
</tr></tbody>
</table>
<p><a name="id1799"></a><img alt="step 4a" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-53.jpg"> Remove the 1 mL syringe from the plastic wrapper. Always use a new syringe. </p>
<table>
<col width="19%">
<col width="33%">
<col width="63%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="top">
<a name="id1804"></a><img alt="grip firmly" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-54.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id1806"></a><img alt="pull cover" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-55.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id1808"></a><img alt="pull plunger" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-56.jpg">
</td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">Firmly grip the needle base. </p></td>
<td class="Botrule" valign="top">
<p class="First">Pull the needle cover straight off. </p>
<p>Throw away the needle cover in the sharps disposal container.</p>
</td>
<td class="Botrule" valign="top">
<p class="First">Pull down the plunger until the top rim of the plunger lines up with the black line of the dose prescribed by your healthcare provider. </p>
<p>You<span class="Bold"> must first </span>fill the syringe with air and put that air into the vial to make it easier to later fill the syringe with liquid.</p>
</td>
</tr>
</tbody>
</table>
<table>
<col width="71%">
<col width="45%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Toprule" valign="top">
<a name="id1824"></a><img alt="insert needle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-57.jpg"><p class="First">Hold the vial with the mixed MYALEPT. Insert the needle into the top of the MYALEPT vial. </p>
</td>
<td class="Botrule Toprule" valign="top">
<a name="id1826"></a><img alt="push plunger" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-58.jpg"><p class="First">Push the plunger down all the way, to fill the vial with air.</p>
</td>
</tr></tbody>
</table>
<table>
<col width="23%">
<col width="35%">
<col width="28%">
<col width="29%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="top">
<a name="id1835"></a><img alt="turn upside down" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-59.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id1837"></a><img alt="line up plunger" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-60.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id1839"></a><img alt="air pocket" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-61.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id1841"></a><img alt="remove air pocket" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-62.jpg">
</td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top">
<p class="First">With the needle still in the vial, turn the vial and syringe upside down. </p>
<p>Keep the whole needle in the liquid. It is okay if the plunger moves down.</p>
</td>
<td class="Botrule" valign="top"><p class="First">Pull down the plunger until the top rim of the plunger lines up with the black line of the dose prescribed by your healthcare provider.</p></td>
<td class="Botrule" valign="top">
<p class="First">Check to see if there is an air pocket in the syringe. </p>
<p>If you see an air pocket, tap the side of the syringe to move the air pocket to the top of the syringe.</p>
</td>
<td class="Botrule" valign="top">
<p class="First">Push the plunger up to remove the air pocket. </p>
<p>You must remove the air pocket to be able to fill the syringe with a full dose of MYALEPT.</p>
</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Tip: If your prescribed dose is more than 1 mL, you will need to use 2 separate injections to take your full daily dose. Repeat Step 4 to fill the second syringe.</span></p>
<table>
<col width="32%">
<col width="24%">
<col width="40%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="top">
<a name="id1863"></a><img alt="check for bubbles" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-63.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id1865"></a><img alt="remove bubbles" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-64.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id1867"></a><img alt="align plunger" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-65.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id1869"></a><img alt="remove needle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-66.jpg">
</td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top">
<p class="First">Check to see if there are large air bubbles in the syringe. </p>
<p>If you see large air bubbles in the syringe, tap the side of the syringe to move the air bubbles to the top.<br><br>If there are a few small bubbles left, that is okay.</p>
</td>
<td class="Botrule" valign="top"><p class="First">Push the plunger up to remove as many large air bubbles as you can. </p></td>
<td class="Botrule" valign="top"><p class="First">Pull down the plunger again until the top rim of the plunger lines up with the black line of the dose prescribed by your healthcare provider. </p></td>
<td class="Botrule" valign="top">
<p class="First">Remove the needle from the vial. </p>
<p>Set the vial down. <span class="Bold">Do not</span> set the syringe down.</p>
</td>
</tr>
</tbody>
</table>
<p><span class="Bold">STEP 5: Injecting MYALEPT</span></p>
<p><span class="Bold">For this step, you will need:</span></p>
<table>
<col width="24%">
<col width="15%">
<col width="39%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Toprule" valign="top">
<p class="First">Syringe filled with your<br>MYALEPT dose<br>(from Step 4) </p>
<br><a name="id1896"></a><img alt="filled syringe" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-67.jpg">
</td>
<td class="Botrule Toprule" align="center" valign="top">
<p class="First">Alcohol wipe<br>(from Step 1) </p>
<a name="id1900"></a><img alt="alcohol wipe" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-68.jpg">
</td>
<td class="Botrule Toprule" align="center" valign="top">
<p class="First">Sharps disposal<br>container for used syringes and needles </p>
<a name="id1904"></a><img alt="Sharps disposal container" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-69.jpg">
</td>
</tr></tbody>
</table>
<table>
<col width="53%">
<col width="20%">
<col width="21%">
<col width="21%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="top">
<a name="id1913"></a><img alt="injection site" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-70.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id1915"></a><img alt="clean injection site" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-71.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id1917"></a><img alt="insert in pinched skin" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-72.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id1919"></a><img alt="release skin and inject" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-73.jpg">
</td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top">
<p class="First">Choose an injection site that you will use to inject your MYALEPT. </p>
<p>The recommended injection sites are an area of your body that has the most fat, such as the stomach (abdomen), thigh, or the back of your upper arm.<br><br>You can use the same area of the body for each injection. But be sure to choose a different injection site in that area. </p>
<p>If you inject other medicines you should choose a different site from where you inject MYALEPT. <span class="Bold">Do not </span>inject MYALEPT in the same site as your other medicines.</p>
</td>
<td class="Botrule" valign="top">
<p class="First">Use an alcohol wipe to clean the injection site. </p>
<p>Let the alcohol dry before you move on to 5c.</p>
</td>
<td class="Botrule" valign="top">
<p class="First">Pinch the skin with one hand.  </p>
<p>With the other hand, hold the syringe like a pencil. <br><br>Insert the needle into the skin at an angle. <br><span class="Bold">Do not</span> insert the needle straight up and down. </p>
</td>
<td class="Botrule" valign="top">
<p class="First">Let go of the skin.<br><br>Use your thumb to push the plunger down until it stops. <br></p>
<p>Take the needle out of your skin.	 </p>
</td>
</tr>
</tbody>
</table>
<table>
<col width="32%">
<col width="83%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Important:</span></p>
<p>Inject MYALEPT under the skin (subcutaneous). <br><span class="Bold">Do not</span> inject MYALEPT into a muscle or vein.</p>
<a name="id1951"></a><img alt="dispose of syringe" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-74.jpg">
</td>
<td class="Botrule Toprule" valign="top"><p class="First">Throw away the used syringe with the needle still attached in your sharps disposal container. See “<span class="Bold">Disposing of used needles and syringes</span>? at the end of this IFU.<br><br><span class="Bold">Do not</span> recap the needle. Recapping the needle can lead to a needlestick injury.</p></td>
</tr></tbody>
</table>
<p><span class="Bold">Important: For newborns or infants using MYALEPT, throw away the unused mixed MYALEPT right away. Do not store it for reuse.</span></p>
<p><span class="Bold">Keep the vial of MYALEPT mixed with bacteriostatic water for injection for reuse. Turn the page for instructions on storing the vial.</span></p>
<table>
<col width="29%">
<col width="42%">
<col width="21%">
<col width="23%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="top">
<a name="id1970"></a><img alt="store vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-75.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id1972"></a><img alt="mark calendar" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-76.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id1974"></a><img alt="mark sticker" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-77.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id1976"></a><img alt="place sticker" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-78.jpg">
</td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">Store the vial of mixed MYALEPT in the refrigerator as soon as you are done. </p></td>
<td class="Botrule" valign="top">
<p class="First">Looking at a calendar, count 2 days after the day you mixed the MYALEPT. </p>
<p>For example, if you mixed MYALEPT on Monday, January 2, you would throw it away<span class="Bold"> after your dose </span>on Wednesday, January 4.</p>
</td>
<td class="Botrule" valign="top"><p class="First">Write that date on the stickers found to the right. </p></td>
<td class="Botrule" valign="top"><p class="First">Place the sticker on the vial of mixed MYALEPT. </p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Important:</span></p>
<p><span class="Bold">Stickers to Note the Last Day You Can Use MYALEPT When Mixed with Bacteriostatic Water for Injection</span></p>
<table>
<col width="24%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Toprule" align="center" valign="top">
<a name="id1994"></a><img alt="stickers" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-79.jpg">
</td></tr></tbody>
</table>
<p><span class="Bold">STEP 6:   Disposing of used needles and syringes:</span></p>
<dl>
<dt>•</dt>
<dd>Put your used needles and syringes in a FDA-cleared sharps disposal container right away after use. <span class="Bold">Do not</span> throw away (dispose of) loose needles and syringes in your household trash.</dd>
<dt>•</dt>
<dd>If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:<dl>
<dt>∘</dt>
<dd>made of heavy-duty plastic</dd>
<dt>∘</dt>
<dd>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out</dd>
<dt>∘</dt>
<dd>upright and stable during use</dd>
<dt>∘</dt>
<dd>leak-resistant, and</dd>
<dt>∘</dt>
<dd>properly labeled to warn of hazardous waste inside the container</dd>
</dl>
</dd>
<dt>•</dt>
<dd>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal. </dd>
</dl>
<p><span class="Bold">Common questions</span></p>
<table>
<col width="62%">
<col width="13%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First"> Questions about storing and traveling with MYALEPT </p></td>
<td class="Toprule" valign="top"><p class="First">pages xx-xx</p></td>
</tr>
<tr>
<td valign="top"><p class="First"> Questions about preparing and mixing your dose of MYALEPT </p></td>
<td valign="top"><p class="First">pages xx-xx</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First"> Questions about injecting MYALEPT </p></td>
<td class="Botrule" valign="top"><p class="First">page xx</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Common questions</span></p>
<p><span class="Bold">Questions about storing and traveling with MYALEPT</span></p>
<table>
<col width="5%">
<col width="102%">
<col width="9%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First"><span class="Bold">1Q</span></p></td>
<td class="Toprule" valign="top"><p class="First"><span class="Bold">How do I store a vial of powder (MYALEPT) and mixed MYALEPT?</span></p></td>
</tr>
<tr><td valign="top"></td></tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">A</span></p></td>
<td valign="top">
<p class="First">The vial of powder has a white cap. The vial of mixed medicine is the vial to which you applied the sticker. </p>
<dl>
<dt>•</dt>
<dd>These vials should be kept in their carton in the refrigerator until you are ready to use them</dd>
<dt>•</dt>
<dd>Store these vials in their carton so they can be protected from light</dd>
<dt>•</dt>
<dd>Do not freeze or heat these vials</dd>
</dl>
</td>
<td align="center" valign="top">
<a name="id2048"></a><img alt="medicine vials" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-80.jpg">
</td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">2Q</span></p></td>
<td valign="top"><p class="First"><span class="Bold">How long can I leave a vial of powder or mixed MYALEPT at room temperature?</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">A</span></p></td>
<td valign="top"><p class="First">A vial of powder or MYALEPT mixed with bacteriostatic water for injection can be left at room temperature for up to 4 hours. MYALEPT mixed with sterile water for injection should be used right away. Throw away any unused mixed MYALEPT. If you are unsure about whether you can use a vial of powder or mixed MYALEPT, call 1-855-6MYALEPT.</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">3Q</span></p></td>
<td valign="top"><p class="First"><span class="Bold">What do I do with a vial of powder or mixed MYALEPT if it has been frozen or heated?</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">A</span></p></td>
<td valign="top"><p class="First">If a vial of powder or mixed MYALEPT has been frozen or heated, throw it away in the sharps disposal container.</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">4Q</span></p></td>
<td valign="top"><p class="First"><span class="Bold">What do I do with a vial of mixed MYALEPT if there is not a full dose left?</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">A</span></p></td>
<td valign="top"><p class="First">Ask your healthcare provider how to use or store a vial of mixed MYALEPT that contains less than a full dose.</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">5Q</span></p></td>
<td valign="top"><p class="First"><span class="Bold">How do I take MYALEPT if I am away from home or traveling?</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First"><span class="Bold">A</span></p></td>
<td class="Botrule" valign="top"><p class="First">To take a dose of MYALEPT if you are away from home or traveling, you must take all of your supplies with you. Do not fill a syringe or prepare a dose ahead of time and take it with you.</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Questions about preparing and mixing your dose of MYALEPT</span></p>
<table>
<col width="6%">
<col width="98%">
<col width="11%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First"><span class="Bold">6Q</span></p></td>
<td class="Toprule" valign="top"><p class="First"><span class="Bold">What should I do if I touch the top of a vial after I have cleaned it?</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">A</span></p></td>
<td valign="top"><p class="First">Clean the top of the vial again with a new alcohol wipe.</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">7Q</span></p></td>
<td valign="top"><p class="First"><span class="Bold">What should I do if my dose is written in mg (milligrams), not mL (milliliters)?</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">A</span></p></td>
<td valign="top"><p class="First">If your dose of MYALEPT is written in mg and not mL, call your pharmacist. Your pharmacist can give you your dose in mL. Do not try to prepare a dose of MYALEPT if your dose is in mg.</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">8Q</span></p></td>
<td valign="top"><p class="First"><span class="Bold">What should I do if there are air bubbles or air pockets in the syringe?</span></p></td>
</tr>
<tr><td valign="top"></td></tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">A</span></p></td>
<td valign="top"><p class="First">Follow steps 2g (page xx) and 2h (page xx) to remove air bubbles or an air pocket from the syringe when filling it with liquid. Follow steps 4g (page xx) and 4h (page xx) to remove air bubbles or an air pocket from the syringe when filling it with MYALEPT. <br>Check to see if there are large air bubbles in the syringe. If so, tap the syringe to move the air bubbles to the top. If there are still a few small air bubbles left in the syringe after these steps, that is okay. The air bubbles will not harm you.</p></td>
<td align="center" valign="top">
<a name="id2124"></a><img alt="check forair bubbles" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-81.jpg">
</td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">9Q</span></p></td>
<td valign="top"><p class="First"><span class="Bold">What if the needle comes off the syringe used to mix MYALEPT when I am trying to remove the needle cover?</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">A</span></p></td>
<td valign="top"><p class="First">With the needle cover still on the needle, twist the needle back onto the syringe. Firmly grip the syringe and pull the needle cover straight off. Do not twist the syringe or needle when pulling off the needle cover.</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">10Q</span></p></td>
<td valign="top"><p class="First"><span class="Bold">What if the needle comes off the syringe used to inject MYALEPT when I am trying to remove the needle cover?</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">A</span></p></td>
<td valign="top"><p class="First">With the needle cover still on the needle, firmly push the needle back onto the syringe. Grip the base of the needle as firmly as you can between your index finger and thumb while pulling on the needle cover.</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">11Q</span></p></td>
<td valign="top"><p class="First"><span class="Bold">What do I do if I see foam in a vial of medicine I am mixing?</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">A</span></p></td>
<td valign="top"><p class="First">If foam forms in the vial of medicine as you swirl it, let the vial sit on the work surface until the foam is gone.</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">12Q</span></p></td>
<td valign="top"><p class="First"><span class="Bold">Can I fill a syringe with a dose of mixed MYALEPT and save it to use later?</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First"><span class="Bold">A</span></p></td>
<td class="Botrule" valign="top"><p class="First">A dose of MYALEPT should be taken right after it is mixed. Do not fill a syringe or prepare a dose for later use.</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Questions about injecting MYALEPT</span></p>
<table>
<col width="6%">
<col width="107%">
<col width="2%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First"><span class="Bold">13Q</span></p></td>
<td class="Toprule" valign="top"><p class="First"><span class="Bold">What are some tips for injecting MYALEPT?</span></p></td>
<td class="Toprule" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First"><span class="Bold">A</span></p></td>
<td class="Botrule" valign="top">
<p class="First">Try these tips to help you prepare for your injection with MYALEPT:  </p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Know the steps in the process. </span>To get to know the steps, read this booklet ahead of time. It may help to read the steps out loud. If you have questions about how to inject, make sure to ask your healthcare provider</dd>
<dt>•</dt>
<dd><span class="Bold">Find a place that is clean and well lit in which you can do the injection</span></dd>
<dt>•</dt>
<dd>
<span class="Bold">Ask for help. </span>You may feel more comfortable if a care partner does the injection for you</dd>
<dt>•</dt>
<dd>
<span class="Bold">Put ice on the injection site. </span> You may want to use ice at the injection site, after your injection, to help lessen some of the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> you might feel</dd>
<dt>•</dt>
<dd>
<span class="Bold">Make sure the vial with powder (MYALEPT) is at room temperature before you mix and inject it. </span>To do this, take a vial with powder out of the refrigerator and set it out for 10 to 15 minutes</dd>
</dl>
</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Questions about MYALEPT supplies</span></p>
<table>
<col width="6%">
<col width="107%">
<col width="2%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First"><span class="Bold">14Q</span></p></td>
<td class="Toprule" valign="top"><p class="First"><span class="Bold">How do I obtain the supplies needed to inject MYALEPT?</span></p></td>
<td class="Toprule" valign="top"></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">A</span></p></td>
<td valign="top"><p class="First">The standard supplies needed to inject MYALEPT include needles, syringes, liquid for mixing and a disposal container. Your healthcare provider will give you a prescription for these supplies which can be filled by a retail or hospital pharmacy, or the specialty pharmacy who distributes MYALEPT.</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">15Q</span></p></td>
<td valign="top"><p class="First"><span class="Bold">How do I store the other supplies that are needed to prepare and inject a dose of MYALEPT?</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First"><span class="Bold">A</span></p></td>
<td class="Botrule" valign="top"><p class="First">Store syringes, vials of liquid with colored caps, alcohol wipes, and sharps disposal container at room temperature or at the temperature that is written on the package they came in. Be sure to check the expiration date on the packages of your supplies before use. Do not use expired supplies.</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold"> To learn more about MYALEPT</span></p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Talk with your healthcare provider</span></dd>
<dt>•</dt>
<dd><span class="Bold">Read the Medication Guide that came with MYALEPT. The Medication Guide can help answer your questions about MYALEPT, such as what it is used for, possible side effects, and when to take it</span></dd>
<dt>•</dt>
<dd><span class="Bold">Visit www.MYALEPT.com or call 1-855-6MYALEPT for FREE ongoing support and services</span></dd>
</dl>
<p>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</p>
<p>MYALEPT is a trademark of the AstraZeneca group of companies.</p>
<p>Manufactured for:<br>Amylin Pharmaceuticals, LLC</p>
<p>Wilmington, DE 19850</p>
<p>Distributed by:</p>
<p>AstraZeneca Pharmaceuticals LP</p>
<p>Wilmington, DE 19850</p>
<dl>
<dt> </dt>
<dd>1334130-xx 	Issued June 2014</dd>
</dl>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_3d2d3bf3-796d-4923-9f94-aa5036172bf3"></a><a name="section-19"></a><p></p>
<h1>MYALEPT 11.3 mg Subcutaneous Injection Representative Packaging</h1>
<p class="First">See <span class="Bold">How Supplied</span> section for a complete list of available packages of MYALEPT.</p>
<p><span class="Bold">Rx Only</span><br>NDC 66780-310-01</p>
<p><span class="Bold">MYALEPT™</span><br>(metreleptin) For Injection</p>
<p><span class="Bold">11.3 mg per vial</span></p>
<p><span class="Bold">SUBCUTANEOUS USE ONLY</span></p>
<p><span class="Bold">Dispense the enclosed Medication Guide to each patient.</span></p>
<p>Single-dose vial if reconstituted with Water for Injection. Discard after each use.</p>
<p>Multi-dose vial if reconstituted with Bacteriostatic Water for Injection. Must be used within 3 days after reconstitution.</p>
<div class="Figure">
<a name="id2642"></a><img alt="Principal Display Panel - One Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b6349e72-8bbb-40c6-ab31-89f7b1cce914&amp;name=189c7038-2646-4dfe-b299-7d77e2e7718c-82.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MYALEPT 		
					</strong><br><span class="contentTableReg">metreleptin injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:66780-310</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Metreleptin</strong> (Metreleptin) </td>
<td class="formItem">Metreleptin</td>
<td class="formItem">11.3 mg  in 2.2 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Glycine</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sucrose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Polysorbate 20</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Glutamic Acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:66780-310-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2.2 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125390</td>
<td class="formItem">05/22/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Amylin Pharmaceuticals, LLC
							(196877526)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>AstraZeneca PLC (230790719)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>189c7038-2646-4dfe-b299-7d77e2e7718c</div>
<div>Set id: b6349e72-8bbb-40c6-ab31-89f7b1cce914</div>
<div>Version: 3</div>
<div>Effective Time: 20140630</div>
</div>
</div> <div class="DistributorName">Amylin Pharmaceuticals, LLC</div></p>
</body></html>
